Rob Baltussen

Summary

Affiliation: Erasmus University
Country: The Netherlands

Publications

  1. pmc Cost-effectiveness analysis of cataract surgery: a global and regional analysis
    Rob Baltussen
    iMTA Institute for Medical Technology Assessment, Erasmus University Rotterdam, The Netherlands
    Bull World Health Organ 82:338-45. 2004
  2. ncbi request reprint Iron fortification and iron supplementation are cost-effective interventions to reduce iron deficiency in four subregions of the world
    Rob Baltussen
    WHO CHOICE, Institute for Medical Technology Assessment, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nutr 134:2678-84. 2004
  3. ncbi request reprint The impact of antiretroviral treatment on the age composition of the HIV epidemic in sub-Saharan Africa
    Jan A C Hontelez
    Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    AIDS 26:S19-30. 2012
  4. ncbi request reprint Costs and health effects of breast cancer interventions in epidemiologically different regions of Africa, North America, and Asia
    Martijn T Groot
    Institute for Medical Technology Assessment, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    Breast J 12:S81-90. 2006
  5. pmc The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa
    Jan A C Hontelez
    Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
    PLoS ONE 6:e21919. 2011
  6. ncbi request reprint Cost-effectiveness analysis for priority setting in health: penny-wise but pound-foolish
    Rob Baltussen
    Institute for Medical Technology Assessment, Erasmus Medical Centre Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Int J Technol Assess Health Care 21:532-4. 2005
  7. ncbi request reprint Accounting for the cost of scaling-up health interventions
    Benjamin Johns
    Global Programme on Evidence for Health Policy GPE EQC, World Health Organization, CH 1211 Geneva 27, Switzerland
    Health Econ 13:1117-24. 2004
  8. pmc Cost effectiveness analysis of strategies for tuberculosis control in developing countries
    Rob Baltussen
    Institute for Medical Technology Assessment iMTA, Erasmus Medical Centre, PO Box 1738, 3000 DR Rotterdam, Netherlands
    BMJ 331:1364. 2005
  9. pmc Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries
    Daniel R Hogan
    Harvard Center for Population and Development Studies, Harvard School of Public Health, Cambridge, MA 02138, USA
    BMJ 331:1431-7. 2005
  10. ncbi request reprint Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India
    Filip Meheus
    Institute of Development Policy and Management, University of Antwerp, Antwerp, Belgium
    Trop Med Int Health 11:1715-24. 2006

Collaborators

Detail Information

Publications12

  1. pmc Cost-effectiveness analysis of cataract surgery: a global and regional analysis
    Rob Baltussen
    iMTA Institute for Medical Technology Assessment, Erasmus University Rotterdam, The Netherlands
    Bull World Health Organ 82:338-45. 2004
    ..To estimate the population health effects, costs and cost effectiveness of selected cataract surgery interventions in areas of the world with different epidemiological profiles...
  2. ncbi request reprint Iron fortification and iron supplementation are cost-effective interventions to reduce iron deficiency in four subregions of the world
    Rob Baltussen
    WHO CHOICE, Institute for Medical Technology Assessment, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nutr 134:2678-84. 2004
    ..The results should be interpreted with caution, because evidence of intervention effectiveness predominantly relates to small-scale efficacy trials, which may not reflect the actual effect under expected conditions...
  3. ncbi request reprint The impact of antiretroviral treatment on the age composition of the HIV epidemic in sub-Saharan Africa
    Jan A C Hontelez
    Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    AIDS 26:S19-30. 2012
    ..We quantify the change in the age composition of HIV-infected people in all countries in SSA...
  4. ncbi request reprint Costs and health effects of breast cancer interventions in epidemiologically different regions of Africa, North America, and Asia
    Martijn T Groot
    Institute for Medical Technology Assessment, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    Breast J 12:S81-90. 2006
    ..These findings suggest that treating stage I disease and introducing an extensive breast cancer program are the most cost-effective breast cancer interventions...
  5. pmc The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa
    Jan A C Hontelez
    Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
    PLoS ONE 6:e21919. 2011
    ..Furthermore, there will be a more profound impact on HIV incidence, leading to relatively less annual costs after seven years. The resulting cumulative net costs reach a break-even point after on average 16 years...
  6. ncbi request reprint Cost-effectiveness analysis for priority setting in health: penny-wise but pound-foolish
    Rob Baltussen
    Institute for Medical Technology Assessment, Erasmus Medical Centre Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Int J Technol Assess Health Care 21:532-4. 2005
    ..Without redirecting the focus of economic evaluation research, choosing in health care bears the risk to remain penny-wise but pound-foolish...
  7. ncbi request reprint Accounting for the cost of scaling-up health interventions
    Benjamin Johns
    Global Programme on Evidence for Health Policy GPE EQC, World Health Organization, CH 1211 Geneva 27, Switzerland
    Health Econ 13:1117-24. 2004
    ..Results show changing marginal costs as predicted by economic theory...
  8. pmc Cost effectiveness analysis of strategies for tuberculosis control in developing countries
    Rob Baltussen
    Institute for Medical Technology Assessment iMTA, Erasmus Medical Centre, PO Box 1738, 3000 DR Rotterdam, Netherlands
    BMJ 331:1364. 2005
    ..To assess the costs and health effects of tuberculosis control interventions in Africa and South East Asia in the context of the millennium development goals...
  9. pmc Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries
    Daniel R Hogan
    Harvard Center for Population and Development Studies, Harvard School of Public Health, Cambridge, MA 02138, USA
    BMJ 331:1431-7. 2005
    ..To assess the costs and health effects of a range of interventions for preventing the spread of HIV and for treating people with HIV/AIDS in the context of the millennium development goal for combating HIV/AIDS...
  10. ncbi request reprint Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India
    Filip Meheus
    Institute of Development Policy and Management, University of Antwerp, Antwerp, Belgium
    Trop Med Int Health 11:1715-24. 2006
    ..To identify and quantify the direct and indirect economic cost of treatment for visceral leishmaniasis (VL) with conventional Amphotericin B deoxycholate, currently the first-line treatment in Muzaffarpur...
  11. ncbi request reprint Costs, health effects and cost-effectiveness of alcohol and tobacco control strategies in Estonia
    Taavi Lai
    Department of Public Health, University of Tartu, Estonia
    Health Policy 84:75-88. 2007
    ..To assess the population-level costs, effects and cost-effectiveness of different alcohol and tobacco control strategies in Estonia...
  12. doi request reprint Barriers to access to antiretroviral treatment in developing countries: a review
    Mariana Posse
    Faculty of Economics and Management, Catholic University of Mozambique, Beira, Mozambique
    Trop Med Int Health 13:904-13. 2008
    ..To present a review of barriers impeding people living with HIV/AIDS in developing countries from accessing treatment, and to make recommendations for further studies...